Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 9/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25392655 | 1.00 | MAP4K4 (0.51) | MAP4K4NPC1LMNATP53MAPT | |
| SCHEMBL25390958 | 1.00 | MAP4K4 (0.51) | MAP4K4NPC1LMNATP53MAPT | |
| SCHEMBL25393063 | 0.93 | NPC1 (0.46) | MAP4K4NPC1LMNATP53MAPT | |
| SCHEMBL25393059 | 0.93 | NPC1 (0.46) | MAP4K4NPC1LMNATP53MAPT | |
| SCHEMBL25394959 | 0.93 | NPC1 (0.46) | MAP4K4NPC1LMNATP53MAPT | |
| SCHEMBL25391714 | 0.79 | RAB9A (0.46) | NPC1LMNATP53MAPTMAPK1 | |
| SCHEMBL18129029 | 0.75 | MAP4K4 (0.57) | MAP4K4DGAT2CYP11B2KAT2B | |
| SCHEMBL23730026 | 0.72 | RAB9A (0.46) | MAP4K4LMNAMAPTRAB9AHSD17B10 | |
| SCHEMBL29683665 | 0.72 | PRKCQ (0.53) | MAP4K4KAT2B | |
| SCHEMBL723065 | 0.72 | PRKCQ (0.53) | MAP4K4KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | MAP4K4 2259/4885NPC1 369/4885LMNA 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.